Month: October 2026

The 5 Ps: Building Trust and Predictability in Pharmaceutical Airfreight

Product. Packaging. Pathway. Procedures. Performance. Five interconnected elements that can help the pharmaceutical supply chain move beyond promises and demonstrate reliable, lane-specific performance.

In pharmaceutical logistics, trust is essential. But how do we demonstrate that a temperature-controlled shipment will arrive safely, particularly when it passes through multiple organisations, facilities and environments?

At Airfreight Pharma 2026 in Athens, discussions involving the Cool Chain Association (CCA) explored this challenge, particularly in relation to the development and qualification of cool corridors.

One message stood out: trust cannot be based on assumptions, labels or certifications alone. It must be supported by evidence.

During the discussion on the future of cool corridors, the five Ps were highlighted as a practical way of assessing whether a particular transportation lane is suitable for a pharmaceutical product.

Rather than evaluating individual elements in isolation, the framework considers how the entire logistics process works together.

1. Product: Start with What You Are Protecting

Every pharmaceutical product has its own stability characteristics, storage requirements and tolerance to temperature exposure.

A transportation solution that works for one medicine may not be appropriate for another, even when both products share the same labelled storage range.

Understanding the product’s stability data is therefore the starting point for any lane assessment.

This includes evaluating how the product may respond to temperature excursions, the duration of potential exposure and the risks associated with different environmental conditions.

The discussions in Athens reinforced that the suitability of a cool corridor must always begin with the product itself, rather than the availability of a particular logistics service.

The question is not simply whether a corridor is temperature controlled, but whether its conditions are appropriate for the product being transported.

2. Packaging: Match Protection to the Journey

Packaging provides an important layer of protection against temperature fluctuations during transportation.

However, no packaging solution should be considered independently of the route it will travel.

Passive and active solutions have different operating characteristics, and their effectiveness depends on factors such as ambient conditions, exposure duration, handling procedures and the product’s requirements.

The Athens discussions highlighted how seasonal variations can significantly influence packaging performance.

For example, a solution designed to protect against summer heat may require reassessment when exposed to winter conditions.

Packaging selection should therefore be supported by qualification evidence that reflects the expected transportation environment, including potential delays and worst-case conditions.

Effective packaging is not simply about the technology used. It is about demonstrating that the chosen solution is suitable for the journey.

3. Pathway: Understand Every Step of the Journey

A pharmaceutical shipment does not move through a single controlled environment.

It passes through warehouses, trucks, airports, aircraft and multiple handover points, often involving different organisations.

Each transition introduces potential operational and temperature risks.

The pathway element focuses on understanding the complete journey, including infrastructure capabilities, transfer processes, airport conditions, available capacity and the responsibilities of individual partners.

During Airfreight Pharma 2026, panellists emphasised that airports and transportation lanes cannot be assumed to perform identically.

A process that works successfully at one location may not be suitable at another, where infrastructure, climate, staffing or operating procedures differ.

Even the reverse direction of an established route may require separate assessment.

This makes lane-specific qualification essential.

A reliable pathway is not defined by the route on a map, but by what actually happens to the shipment at every stage.

4. Procedures: Make Reliability Repeatable

Even with the right product knowledge, packaging and infrastructure, operational performance depends on consistent execution.

Standard operating procedures (SOPs) establish how shipments should be handled, monitored and protected throughout the journey.

But procedures must also account for what happens when operations do not go according to plan.

What happens if an aircraft is delayed? Who decides whether a shipment should continue? How quickly can cargo be retrieved from the tarmac? Who is responsible for communicating a potential temperature excursion?

These were among the practical issues raised during the discussions in Athens.

Participants highlighted the importance of clear escalation arrangements, contingency planning and personnel empowered to make timely decisions.

Training is equally critical.

Employees must understand not only what a procedure requires, but why their actions matter to product integrity.

Procedures create consistency. Trained and empowered people make those procedures effective.

5. Performance: Prove That the Process Works

The final P brings the other four together.

Performance is about demonstrating, through reliable evidence, that the transportation process consistently delivers the required outcome.

This may include lane qualification studies, temperature monitoring records, seasonal performance data, handling-time measurements, deviation histories and evidence of effective corrective actions.

Importantly, qualification should not be treated as a one-time exercise.

Infrastructure changes, seasonal conditions, operational disruptions and evolving partner capabilities can all affect a lane’s performance.

Ongoing monitoring and periodic reassessment help ensure that the original qualification remains relevant.

The Athens discussions reinforced that greater transparency around operational performance can strengthen confidence between pharmaceutical manufacturers and logistics providers.

It also provides an opportunity to identify recurring weaknesses and improve processes before they lead to product loss.

Trust is built when performance can be demonstrated, measured and continuously improved.

Five Ps, One Connected Supply Chain

The strength of the five Ps lies in their interdependence.

The right packaging cannot compensate indefinitely for an unsuitable pathway. Well-designed procedures cannot eliminate risk if staff are not adequately trained. And performance data has limited value if it is not connected to the product requirements and operating conditions it is intended to assess.

This is particularly relevant to the development of cool corridors, where multiple independent organisations must deliver a coordinated end-to-end service.

The framework also highlights why collaboration and information sharing are essential.

Manufacturers understand product stability. Packaging providers understand protective capabilities. Airlines, freight forwarders, ground handlers and transport operators understand different aspects of the physical journey.

No single stakeholder holds all the information required to assess the entire process.

Bringing that knowledge together creates a stronger foundation for risk management, operational predictability and continuous improvement.

From Qualification to Confidence

As the pharmaceutical airfreight industry explores more scalable and cost-effective temperature-controlled solutions, the need for consistent, evidence-based assessment will become increasingly important.

The five Ps offer a useful framework for structuring those conversations, helping stakeholders identify what needs to be understood, controlled and demonstrated before a lane can be considered suitable.

For the Cool Chain Association, the discussions at Airfreight Pharma 2026 reinforced the importance of bringing different parts of the supply chain together to share expertise, challenge assumptions and improve industry practices.

Because ultimately, reliable pharmaceutical logistics is not about eliminating every possible risk. It is about understanding those risks, managing them effectively and demonstrating that the process performs as intended.

And that starts with getting all five Ps right.

AI Is Advancing Pharma Logistics. But Is the Industry Ready to Share Its Data?

Artificial intelligence promises smarter, more resilient pharmaceutical supply chains. Yet discussions at Airfreight Pharma 2026 in Athens highlighted a fundamental challenge: technology is advancing faster than the industry’s ability to share, interpret and act on data.

Pharmaceutical airfreight has never had access to more information. Temperature monitoring, shipment tracking, predictive analytics and increasingly sophisticated digital tools are creating new opportunities to understand and manage supply-chain risks.

But more data does not automatically mean better decisions.

At Airfreight Pharma 2026, hosted in Athens with the participation of the Cool Chain Association (CCA), industry stakeholders explored how artificial intelligence, data transparency and operational expertise could improve product protection and supply-chain resilience.

A recurring theme was clear: the real challenge is not simply collecting data, but turning it into trusted, actionable intelligence across the entire supply chain.

The Data Sharing Dilemma

Pharmaceutical shipments pass through multiple organisations, each responsible for a different stage of the journey.

Manufacturers, freight forwarders, airlines, ground handlers and transport providers all generate valuable operational data. Yet that information is often held in separate systems, governed by different commercial agreements and subject to varying data protection requirements.

Data governance and security are essential, particularly in a highly regulated industry. However, these requirements can also make it difficult to share the information needed to develop a complete picture of shipment performance.

The result is a paradox: the industry is investing heavily in visibility, while the information required to make end-to-end decisions may remain fragmented.

The discussions in Athens highlighted the need to move beyond simply increasing the volume of available data towards establishing greater clarity over what information is needed, who can access it and how it can be used responsibly.

Greater transparency does not necessarily mean sharing everything. It means sharing the right information, with the right stakeholders, at the right time.

AI Can Identify Risks. People Must Still Make Decisions.

Artificial intelligence and digital simulation offer significant potential for pharmaceutical logistics.

During the event, participants explored how digital twins could help assess operational variables, simulate disruptions and understand how different conditions might affect temperature-controlled shipments.

Such capabilities could support more informed lane qualification, improved contingency planning and better identification of potential failure points.

However, the quality of any AI-driven insight depends on the reliability and relevance of the underlying data.

A temperature reading without sufficient operational context may not explain what happened to a shipment, why it happened or what action should follow.

Product stability, packaging performance, route conditions and handling procedures must all be considered before interpreting the significance of an event.

The discussions also reinforced the importance of human judgement.

When a shipment is delayed on the tarmac or an unexpected operational disruption occurs, the time available to intervene may be measured in minutes.

Data can alert stakeholders to a developing risk, but trained personnel must understand the situation, assess the options and act.

This makes continued investment in people, training and operational decision-making just as important as investment in technology.

From Visibility to Evidence-Based Trust

For pharmaceutical manufacturers, visibility is valuable, but it is not the ultimate objective.

The priority is protecting product integrity and ensuring that medicines reach patients safely.

During the cool-corridor discussions, participants repeatedly emphasised that confidence in a logistics process must be supported by evidence.

Temperature records, qualification studies, operational performance data, deviation histories and demonstrated risk controls all contribute to that confidence.

AI and analytics can help organisations interpret this information and identify opportunities for improvement. But technology cannot replace the need for reliable evidence that a process performs consistently.

This distinction becomes particularly important when evaluating temperature-controlled corridors.

A route that performs well under one set of conditions may behave differently during another season, with different packaging or when operational arrangements change.

Understanding these variables requires more than an isolated dataset. It requires collaboration between the organisations responsible for each stage of the journey.

Collaboration Is the Next Step

The pharmaceutical logistics industry has made considerable progress in monitoring technology, digitalisation and data collection.

The next opportunity lies in connecting those capabilities more effectively.

This does not require organisations to abandon commercial confidentiality or compromise data protection. It requires a shared understanding of which information is essential for product protection, how it should be governed and how it can support collective learning.

Through its community of stakeholders across the temperature-controlled supply chain, the Cool Chain Association has an important role in encouraging these conversations.

Better collaboration around data could help the industry identify recurring operational weaknesses, improve procedures, strengthen lane qualification and reduce avoidable inefficiencies.

It could also help organisations move from reacting to individual shipment problems towards understanding and addressing their underlying causes.

That is where the potential of AI becomes particularly valuable: not simply predicting what might go wrong, but helping the industry learn how to prevent it.

Technology Will Advance. Trust Must Be Earned.

The discussions at Airfreight Pharma 2026 demonstrated that artificial intelligence will continue to influence the future of pharmaceutical logistics.

But successful adoption will require more than investment in algorithms, platforms and monitoring devices.

It will require high-quality data, responsible governance, transparent collaboration and continued investment in the people who interpret information and make critical decisions.

The industry’s opportunity is not simply to become more data-driven. It is to become more evidence-driven, more collaborative and ultimately more predictable.

Because in pharmaceutical logistics, better decisions are not just about efficiency.

They are about protecting products, reducing risk and maintaining the trust of the patients who depend on them.


Working together to improve the temperature-sensitive supply chain to reduce food loss and waste in the perishables sector as well as benefiting the pharma community.

Registered Address
9 Rue de Siegelbach
L-5361 Schrassig
Grand Dutchy of Luxembourg


© Cool Chain Association. All rights reserved. Built by Meantime Communications.